HIK.L - Hikma Pharmaceuticals PLC

LSE - LSE Delayed Price. Currency in GBp
1,704.50
+17.00 (+1.01%)
At close: 4:35PM GMT
Stock chart is not supported by your current browser
Previous Close1,687.50
Open1,686.00
Bid1,601.00 x 16300
Ask1,840.00 x 34600
Day's Range1,680.20 - 1,737.50
52 Week Range814.20 - 2,089.00
Volume317,792
Avg. Volume703,498
Market Cap4.115B
Beta (3Y Monthly)0.53
PE Ratio (TTM)N/A
EPS (TTM)-335.10
Earnings DateMar 14, 2017 - Mar 20, 2017
Forward Dividend & Yield0.19 (1.05%)
Ex-Dividend Date2018-08-23
1y Target Est24.10
  • Business Wire9 days ago

    Hikma Demonstrates Support for US Pharmacists and Patient Safety

    Activities at upcoming ASHP conference include sponsorship of important symposium advancing patient safety practices

  • Reuters10 days ago

    Royal Mail seen dropping out of top British stock index

    Postal company Royal Mail (RMG.L) is set to lose its place in the FTSE 100 (.FTSE), while insurer Hiscox (HSX.L) is likely to join Britain's top stock index in a reshuffle next week, analysts said. Demotion from the blue-chip index would come just as Royal Mail heads into its busiest time of year, as Britons send millions of greeting cards to family and friends in the run-up to Christmas. The possible swap comes after Royal Mail unveiled a broad review of its operations as it battles to cut costs after reporting a 25 percent drop in half-year profit.

  • Theravance's Respiratory Disease JAK Inhibitor Enters Phase I
    Zacks11 days ago

    Theravance's Respiratory Disease JAK Inhibitor Enters Phase I

    Theravance (TBPH) doses the first patient in a phase I study on novel JAK inhibitor, TD-8236, for treating serious respiratory diseases.

  • Theravance JAK Inhibitor Enters Phase II for Crohn's Disease
    Zacks18 days ago

    Theravance JAK Inhibitor Enters Phase II for Crohn's Disease

    Theravance (TBPH) doses the first patient in a phase II Crohn's disease study on JAK inhibitor, TD-1473.

  • U.K. Economy Grows at Fastest Pace in Nearly a Year: 5 Picks
    Zacks3 months ago

    U.K. Economy Grows at Fastest Pace in Nearly a Year: 5 Picks

    The football World Cup and unexpectedly warm weather led to a pickup in consumer spending.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of HIK.L earnings conference call or presentation 15-Aug-18 8:30am GMT

    Half Year 2018 Hikma Pharmaceuticals PLC Earnings Call

  • Hikma Pharmaceuticals Appoints Kristy Ronco Executive Vice President, Sales and Marketing, Generics
    Business Wire4 months ago

    Hikma Pharmaceuticals Appoints Kristy Ronco Executive Vice President, Sales and Marketing, Generics

    Hikma Pharmaceuticals USA Inc., a wholly owned subsidiary of Hikma Pharmaceuticals PLC , today announced the appointment of Kristy Ronco as Executive Vice President, Sales and Marketing for its Generics Division.

  • Calculating The Fair Value Of Hikma Pharmaceuticals PLC (LON:HIK)
    Simply Wall St.4 months ago

    Calculating The Fair Value Of Hikma Pharmaceuticals PLC (LON:HIK)

    I am going to run you through how I calculated the intrinsic value of Hikma Pharmaceuticals PLC (LON:HIK) by projecting its future cash flows and then discounting them to today’sRead More...

  • Reuters4 months ago

    Commodities slide pulls FTSE to three-and-a-half month closing low

    By Kit Rees and Helen Reid LONDON (Reuters) - Britain's top share index sank on Wednesday as emerging markets stress and a sharp selloff in commodities drove down stocks across Europe, with investors running ...

  • Hikma impresses the City with raised forecasts for 2018
    The Telegraph4 months ago

    Hikma impresses the City with raised forecasts for 2018

    Hikma impresses the City with raised forecasts for 2018

  • Reuters4 months ago

    Hikma sees higher full-year revenue, shares climb

    The Jordanian drugmaker said it sold more injectable opioids in the United States due to a supply shortage, and had a better-than-forecast performance in generics for the first half of the year as its prices proved more resilient than expected. The higher forecast in generics comes as global generic drugmakers with operations in the U.S. cut profit forecasts because of pricing pressure. Novartis said last month that 2018 sales at its generics unit, Sandoz, would fall in the low single-digit percentages, after previously holding out hopes for them to remain steady.

  • Should You Be Concerned About Hikma Pharmaceuticals PLC’s (LON:HIK) Investors?
    Simply Wall St.4 months ago

    Should You Be Concerned About Hikma Pharmaceuticals PLC’s (LON:HIK) Investors?

    I am going to take a deep dive into Hikma Pharmaceuticals PLC’s (LON:HIK) most recent ownership structure, not a frequent subject of discussion among individual investors. When it comes toRead More...

  • Fentanyl maker joins lawsuit to block Nevada execution plan
    Associated Press4 months ago

    Fentanyl maker joins lawsuit to block Nevada execution plan

    LAS VEGAS (AP) — A maker of the powerful synthetic opioid fentanyl joined a bid Monday to block the use of its product in what would be the first execution in Nevada in more than 12 years using a three-drug combination never before tried in any state.

  • Reuters5 months ago

    Hikma raising injectable opioids output to help ease shortage at U.S. hospitals

    London-listed pharmaceutical group Hikma said on Wednesday it was increasing its supply of hydromorphone to U.S. hospitals to help ease a shortage of injectable opioids used to treat patients. Injectable opioid painkillers, which hospitals use to manage pain after operations and in terminal illness, have been in short supply for more than a year largely due to production problems at Pfizer, the biggest supplier of the drugs. Pfizer has said it is making progress on its recovery plan, but it estimates that the supply of some of its injectables will not be fully restored until later this year or in 2019.

  • Business Wire5 months ago

    Hikma Acts to Ease Critical Shortage of Pain Medications Needed by US Hospitals and Their Patients

    Hikma Pharmaceuticals PLC (the Hikma Group) (HIK.L) (NASDAQ Dubai: HIK) (HKMPY), the multinational generic pharmaceutical company, announced today that its US business has begun releasing significant quantities of hydromorphone to US hospital customers to help ease a current shortage of injectable opioids used to treat patients. In response to this shortage, Hikma released more than five million hydromorphone 2ml vials to US hospitals during June, and expects to release another three million vials during July. The current US hospital shortage of injectable opioids used for patient pain management occurred when a significant supplier to the US market temporarily ceased manufacturing.

  • Reuters7 months ago

    Hikma reaffirms full-year revenue forecast, cites better generics business

    The drugmaker, which was forced to cut revenue guidance for its generics business three times in 2017, said it continued to expect revenue from the business to be between $550 million (407 million pounds) and $600 million in 2018. Sigurdur Olafsson, former generics chief at drug giant Teva Pharmaceuticals (TEVA.TA), was named Hikma's chief executive officer in February. The company suffered a setback in March for its generic version of GlaxoSmithKline's (GSK.L) blockbuster lung drug Advair, after the U.S. Food and Drug Administration asked Hikma to conduct a further clinical study evaluating the drug, dashing hopes to get it to the market this year.